127 related articles for article (PubMed ID: 11742498)
1. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.
Cioffi CL; Garay M; Johnston JF; McGraw K; Boggs RT; Hreniuk D; Monia BP
Mol Pharmacol; 1997 Mar; 51(3):383-9. PubMed ID: 9058592
[TBL] [Abstract][Full Text] [Related]
3. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
McPhillips F; Mullen P; MacLeod KG; Sewell JM; Monia BP; Cameron DA; Smyth JF; Langdon SP
Carcinogenesis; 2006 Apr; 27(4):729-39. PubMed ID: 16332724
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides combined transfection on the human ovarian carcinoma transplanted subcutaneously in nude mice].
Wu YZ; Ren QL; Yang SF; Chen XP; Li SL
Zhonghua Fu Chan Ke Za Zhi; 2003 Jun; 38(6):359-61. PubMed ID: 12895380
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of C-erbB-2 and C-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nude mice].
Wu YZ; Ren QL; Li SL
Ai Zheng; 2003 Aug; 22(8):836-9. PubMed ID: 12917030
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
7. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
9. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
12. [Proliferation inhibition and apoptosis onset in human ovarian carcinoma cell line SKOV3 induced by Genistein].
Li Y; Mi C
Ai Zheng; 2003 Jun; 22(6):586-91. PubMed ID: 12948406
[TBL] [Abstract][Full Text] [Related]
13. Liposome-C-erbB2 antisense oligodoxynucleotides in human ovarian cancer cells.
Shen M; Feng Y; Ge B; Wu Z; Zhu M
Chin Med J (Engl); 2001 Jul; 114(7):735-7. PubMed ID: 11780339
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of c-Raf expression induces apoptosis in tumor cells.
Lau QC; Brüsselbach S; Müller R
Oncogene; 1998 Apr; 16(14):1899-902. PubMed ID: 9583688
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
17. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
18. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.
Chang HL; Su JH; Yeh YT; Lee YC; Chen HM; Wu YC; Yuan SS
Cancer Lett; 2008 Aug; 267(1):85-95. PubMed ID: 18430509
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Khatib AM; Fallavollita L; Wancewicz EV; Monia BP; Brodt P
Cancer Res; 2002 Oct; 62(19):5393-8. PubMed ID: 12359742
[TBL] [Abstract][Full Text] [Related]
20. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
